00:28 , May 24, 2019 |  BC Innovations  |  Emerging Company Profile

Anima opens new target space in translational control

Anima Biotech’s answer to undruggable targets is to go after the machinery that turns their mRNA into protein, adding a new approach to the gene regulation tool kit. The strategy should give Anima a leg...
20:10 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest miR-584-5p could help treat medulloblastoma. In patient tissue samples or tumor cells from patient-derived xenograft (PDX) mouse models of medulloblastoma, miR-584-5p levels were lower...
17:40 , Oct 19, 2018 |  BC Week In Review  |  Company News

Revolution acquiring Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
22:17 , Oct 16, 2018 |  BC Extra  |  Company News

Revolution acquiring fellow Third Rock company Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and...
19:54 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
15:05 , Apr 27, 2018 |  BioCentury  |  Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and...
13:59 , Apr 24, 2018 |  BC Extra  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
19:21 , Nov 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Fragile X syndrome Mouse studies suggest inhibiting the eIF4E-eIF4G1 interaction could help treat fragile X syndrome. In a mouse model of fragile X syndrome, a tool compound that inhibits the eIF4E-eIF4G1 interaction increased dendritic...
18:36 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting the MKNK1 - MKNK2 - eIF4E axis could help treat pain. In a mouse model of inflammatory pain, knock-in of an elF4E variant that cannot be phosphorylated by MKNK1...